


- Di
Cont
- Claim 24: The method of claim 23, wherein said mammalian IL-TIF/IL-21 is human IL-TIF/IL-21.
- Claim 25: The method of claim 24, wherein said human IL-TIF/IL-21 is encoded by SEQ ID NO: 25 or 26.
- Claim 26: The method of claim 22, wherein said cell is a human cell.
- Claim 27: The method of claim 22, further comprising inducing production of an acute phase protein, production of which is regulated by STAT 3 transcription factor.
- Claim 28: The method of claim 26, wherein said cell is a liver cell.
- Claim 29: The method of claim 27, wherein said acute phase protein is human serum amyloid A, *1 chymotrypsin, or haptoglobin.
- Claim 30: The method of claim 24, wherein said human IL-TIF/IL-21 also stimulates expression of STAT 1 transcription factor.
- Claim 31: The method of claim 24, wherein said mammalian IL-TIF/IL-21 is murine IL-TIF/IL-21.
- Claim 32: The method of claim 31, wherein said murine IL-TIF/IL-21 also stimulates expression of STAT 5 transcription factor.

REMARKS

Entry of the amendment is requested.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.


Norman D. Hanson, Esq.
Registration No. 30,946